Tag results:

melanoma

New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma

[Advances in Therapy] The authors analyze and discuss the novel therapies for advanced basal cell carcinoma and squamous cell carcinoma to obtain a sharper perspective of the available treatment options.

Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

[Lyell Immunopharma, Inc.] Lyell Immunopharma, Inc. announced that the US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.

The Effect of a Static Magnetic Field and Baicalin or Baicalein Interactions on Amelanotic Melanoma Cell Cultures (C32)

[Molecular Biology Reports] The authors evaluated the simultaneous exposure of melanoma cells to flavones and the static magnetic fields that were generated by permanent magnets on the gene expression and the activity of the antioxidant enzymes that were associated with the antioxidant defense system.

BRAF Inhibitors Reprogram Cancer-Associated Fibroblasts to Drive Matrix Remodeling and Therapeutic Escape in Melanoma

[Cancer Research] BRAF inhibitor induced BRAF-CRAF heterodimerization and subsequent activation of ERK signaling in cancer-associated fibroblasts, leading to inactivation of the β-catenin destruction complex.

Decursin Prevents Melanogenesis by Suppressing MITF Expression through the Regulation of PKA/CREB, MAPKs, and PI3K/Akt/GSK-3β Cascades

[Biomedicine & Pharmacotherapy] Decursin exhibited no cytotoxicity and significantly reduced intracellular tyrosinase activity and melanin content in B16F10 melanoma cells.

Exosome-Mediated Delivery of Transforming Growth Factor-β Receptor 1 Kinase Inhibitors and Toll-Like Receptor 7/8 Agonists for Combination Therapy of Tumors

[Acta Biomaterialia] Combination therapy with the transforming growth factor-β receptor I kinase inhibitor SD-208 and a toll-like receptor-7/8 agonist resiquimod was examined along with serum-derived exosomes as versatile carriers and may serve as a promising strategy to treat melanoma and prostate cancer.

Popular